ACH-3102 + Sovaldi = 100%


Shares of Achillion Pharmaceuticals (ACHN +9.5%) pop on higher volume in response to the company's disclosure that its HCV product candidate, ACH-3102 in combination with Sovaldi (sofosbuvir) cured 12 of 12 patients in a Phase 2 clinical trial. In an interim analysis, 100% of the patients remained HCV RNA undetectable four weeks after completing therapy. Twelve additional patients will now be enrolled in the trial where they will begin six weeks of treatment with once-daily ACH-3102 and sofosbuvir, without ribavirin.

From other sites
Comments (5)
  • Investing Doc
    , contributor
    Comments (1038) | Send Message
     
    Considering that Sofosbuvir achieves excellent efficacy on its own and the size of this trial, color me less than impressed.
    15 Aug 2014, 11:10 AM Reply Like
  • canb888
    , contributor
    Comments (703) | Send Message
     
    Could have been completely due to Sovaldi. Bayer could start Aspirin + Sovaldi and could they claim 10 out of 10 cured due to Aspirin? Long: GILD
    15 Aug 2014, 12:26 PM Reply Like
  • WalkTheTalk
    , contributor
    Comments (466) | Send Message
     
    Sofosbuvir plus ribavirin (RBV)has only 76% of SVR12 rate comparing to 100% SVR12 rate from Sofsbuvir plus ACH3102 in genotype I patient population. So Achillion's regimen is significantly better than the current FDA approved regimen from Gilead. However, the current data from Achillion is preliminary result.

     

    Of course Aspirin may help to reduce someone's headache to think clearly.
    15 Aug 2014, 01:11 PM Reply Like
  • Buzzly3
    , contributor
    Comments (115) | Send Message
     
    I have been following the HCV/HCB field for a long time. Since when Virologic Response Rate for 4 weeks (SVR4) is considered as "cure"? Go ask those HCB/HCV patients who have "undetectable" virus load at the moment of ending treatment only to see the virus come back in 3 months.

     

    SVR12 is the minimum standard.
    15 Aug 2014, 02:34 PM Reply Like
  • Investing Doc
    , contributor
    Comments (1038) | Send Message
     
    If by preliminary result you mean an uncontrolled trial with an n of 12, then, yes, it's preliminary. With that sample size, sofosbuvir alone easily could have accounted for the entirety of the treatment effect. Let's not get too crazy here.
    15 Aug 2014, 01:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs